Rifampicin and Bedaquiline: New Insights into Treating Tuberculosis

Mengqi Gu

2022

Abstract

Tuberculosis (TB), the Mycobacterium tuberculosis infection, remains as a severe issue around the globe, killing 1.4 million people in 2019. In this review, rifampicin, a major component of multidrug regimen, and bedaquiline, a novel drug specifically treats multidrug-resistant TB, are discussed and compared. Rifampicin (Rif) inhibits RNA polymerase by binding to the ß subunit and blocks the elongation of transcription, while bedaquiline inhibits the F-ATP synthase by preventing c-ring rotation when it binds to the c subunit. However, multidrug-resistant TB (MDR-TB) has become severe. Mutations can result in key amino acid substitutions in conformational changes of RNA polymerase, disabling rifampicin to bind. New techniques and possibilities in the mode of delivery are also explored, as oral rifampicin can be improved by solid self-nanoemulsifying drug delivery system (S-SNEDDS) and bedaquiline can be improved by inhalation and long-acting injection.

Paper Citation

in Harvard Style

Gu M. (2022). Rifampicin and Bedaquiline: New Insights into Treating Tuberculosis. In Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB, ISBN 978-989-758-595-1, pages 1179-1187. DOI: 10.5220/0011382200003443

in Bibtex Style

@conference{icbeb22,
author={Mengqi Gu},
title={Rifampicin and Bedaquiline: New Insights into Treating Tuberculosis},
booktitle={Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB,},
year={2022},
pages={1179-1187},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0011382200003443},
isbn={978-989-758-595-1},
}

in EndNote Style

TY - CONF

JO - Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB,
TI - Rifampicin and Bedaquiline: New Insights into Treating Tuberculosis
SN - 978-989-758-595-1
AU - Gu M.
PY - 2022
SP - 1179
EP - 1187
DO - 10.5220/0011382200003443